Literature DB >> 26024910

The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients.

Alpen B Patel1, Stephen F Bansberg2, Charles H Adler3, David G Lott2, Lisa Crujido2.   

Abstract

OBJECTIVE: Analyze demographic data collected over a 25-year experience of 718 patients with spasmodic dysphonia (SD) who have been treated with botulinum toxin-A (BoNT-A) and compare our data with previously published studies.
METHODS: Seven hundred eighteen patients with SD were treated with 6621 BoNT-A injections at Mayo Clinic Arizona between 1989 and 2014. All patients were treated by the same physician team. Background demographic data for each patient were recorded.
RESULTS: Of 718 patients, 557 patients were female (77.6%). Six hundred sixty of 718 (91.8%) patients had adductor SD (AdSD), and 58 of 718 (8.1%) patients had abductor SD (AbSD). Average age of onset was 51 years. Of 718 patients, 378 (52.6%) had vocal tremor (VT); VT was present in 54.4% of AdSD patients and 32.1% of AbSD patients. Thirty-seven of 718 (5.2%) patients had other dystonias, including cervical dystonia (2.3%), blepharospasm (1.4%), limb dystonia (1.1%), and oromandibular dystonia (0.3%). A positive family history of SD was present in only 6 of 718 patients (0.8%) and of other dystonias in 11 of 718 patients (1.5%).
CONCLUSIONS: Spasmodic dysphonia is a chronic and potentially disabling focal laryngeal dystonia. The Mayo Clinic Arizona SD experience compares to prior reports and reveals a female preponderance, onset in middle age, infrequent hereditary pattern, high co-occurrence of VT, and low co-occurrence of other dystonias.
© The Author(s) 2015.

Entities:  

Keywords:  botulinum toxin; dysphonia; dystonia; spasmodic dysphonia; voice

Mesh:

Substances:

Year:  2015        PMID: 26024910     DOI: 10.1177/0003489415588557

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  11 in total

1.  Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.

Authors:  Priyesh N Patel; Edmond K Kabagambe; Jennifer C Starkweather; Matthew Keller; Vahram Gamsarian; Jane Lee; Vishnutheert Kulkarni; C Gaelyn Garrett; David O Francis
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-04-01       Impact factor: 6.223

Review 2.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

3.  Characterizing the Normative Voice Tremor Frequency in Essential Vocal Tremor.

Authors:  Cristen Paige; Bridget L Hopewell; Vahram Gamsarian; Brett Myers; Priyesh Patel; C Gaelyn Garrett; David O Francis
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-12-01       Impact factor: 6.223

4.  Defining differences in patient characteristics between spasmodic dysphonia and laryngeal tremor.

Authors:  Priyesh N Patel; Edmond K Kabagambe; Jennifer C Starkweather; Matthew Keller; Zaki A Ahmed; Simone C Gruber; Jordan S Akins; C Gaelyn Garrett; David O Francis
Journal:  Laryngoscope       Date:  2018-11-13       Impact factor: 3.325

Review 5.  Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30-year experience.

Authors:  Andrew Blitzer; Mitchell F Brin; Kristina Simonyan; Laurie J Ozelius; Steven J Frucht
Journal:  Laryngoscope       Date:  2017-12-08       Impact factor: 3.325

6.  Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial.

Authors:  Masamitsu Hyodo; Asuka Nagao; Kento Asano; Masahiko Sakaguchi; Kenji Mizoguchi; Koichi Omori; Yasuhiro Tada; Hiromitsu Hatakeyama; Nobuhiko Oridate; Kensei Naito; Yoshihiro Iwata; Hirotaka Shinomiya; Hirotaka Hara; Tetsuji Sanuki; Eiji Yumoto
Journal:  Eur J Neurol       Date:  2021-01-23       Impact factor: 6.089

Review 7.  Speech-Language Pathology Evaluation and Management of Hyperkinetic Disorders Affecting Speech and Swallowing Function.

Authors:  Julie M Barkmeier-Kraemer; Heather M Clark
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-09-21

8.  Post-treatment clinical course following botulinum toxin injection therapy for adductor spasmodic dysphonia: Analysis of data from a placebo-controlled, randomized, double-blinded clinical trial in Japan.

Authors:  Kahori Hirose; Kento Asano; Masahiko Sakaguchi; Asuka Nagao; Maya Nakahira; Nao Doi; Taisuke Kobayashi; Masamitsu Hyodo
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-09-28

9.  Demographics and coexisting tremor, cervical dystonia and vocal fold disorders in a group of patients with spasmodic dysphonia.

Authors:  Selmin Karatayli Ozgursoy; Emily R Vargas; Michael G Heckman; Amy L Rutt
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-06       Impact factor: 2.124

Review 10.  Botulinum Toxin Therapy: A Series of Clinical Studies on Patients with Spasmodic Dysphonia in Japan.

Authors:  Masamitsu Hyodo; Kento Asano; Asuka Nagao; Kahori Hirose; Maya Nakahira; Saori Yanagida; Noriko Nishizawa
Journal:  Toxins (Basel)       Date:  2021-11-25       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.